Welcome to our dedicated page for Avantor SEC filings (Ticker: AVTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avantor, Inc. filings document operating results, financial condition and segment reporting for a life science tools company serving life sciences and advanced technology customers. Recent 8-K reports furnish quarterly and annual earnings releases, non-GAAP measures such as adjusted EBITDA and free cash flow, guidance references, and the realignment of reportable segments into VWR Distribution & Services and Bioscience & Medtech Products, including recast historical segment information.
The company’s proxy and current reports also disclose governance matters, director elections, board committee assignments, executive officer transitions, compensation arrangements and annual meeting materials. These filings frame Avantor’s public-company disclosures around its product and services portfolio, leadership structure and shareholder voting matters.
Form 4 summary: Steven W. Eck, SVP & Chief Accounting Officer of Avantor, Inc. (AVTR), reported a sale of 3,476 shares of common stock on 08/05/2025 at a price of $11.39 per share. Beneficial ownership following the reported transaction is 55,068 shares. The Form 4 was signed by attorney-in-fact Scott Baker on 08/06/2025. No derivative securities are reported on Table II.
Form: Form 144 notice relating to Avantor, Inc. (Issuer stated: Avantor Inc).
Transaction: Proposed sale of 3,476 common shares through Merrill (address: 8890 Lyra Drive 5th Floor Columbus OH 43240) with an aggregate market value of $39,592.00. Approximate sale date is 08/05/2025 on the NYSE. Total shares outstanding reported: 681,738,675.
Acquisition: 1,033 shares were acquired via a Restricted Stock Grant Vest from Avantor Inc on 07/31/2025 with payment dated 07/31/2025. The filer reports Nothing to Report for securities sold in the past three months. Several filer identification/contact fields (e.g., CIK) are blank in the provided extract.
Form 4 filed for Avantor, Inc. (AVTR) reporting insider Steven W. Eck, SVP & Chief Accounting Officer. The report discloses a 07/31/2025 transaction coded F, described as shares withheld to cover tax withholding on vested RSUs.
- Withheld shares: 1,385
- Price shown: $13.44
- Beneficially owned after transaction: 58,544 shares (Direct)
- Filing signature/date: /s/ Scott Baker, Attorney-in-Fact, 08/04/2025
This is a routine tax-withholding event following RSU vesting; no open-market sale or derivative transactions are reported.
Avantor, Inc. (AVTR) – SEC Form 4 filing
Company insider Corey Walker, President of Laboratory Solutions, reported a routine tax-related share withholding on 21 June 2025. The filing shows 2,730 common shares (transaction code F) were surrendered at an indicated price of $13.57 to satisfy statutory withholding obligations triggered by the vesting of restricted stock units (RSUs). After the transaction, Walker continues to hold 231,271 shares directly.
No derivative security activity, 10b5-1 plan disclosure, or additional insider transactions were reported. The small size of the disposition (≈1.2 % of Walker’s post-transaction holdings) and its tax-withholding nature make the event immaterial to the company’s capital structure and unlikely to influence the investment thesis for AVTR.